Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On April 18, 2005, the GSK Trust transferred 24,870 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on April 19, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the mechanics of the share transfer and the nature of the GSK Trust as a discretionary trust for employees and former employees.
Key Facts for Investor Verification
- 24,870 Ordinary Shares were transferred from the GSK Trust to employee plan participants on April 18, 2005.
- Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.
- This filing does not include financial results or operational updates for the period.